Phenobarbital pharmacokinetics in neonates and infants during extracorporeal membrane oxygenation

Abstract

Introduction:

The disposition of drugs is potentially changed due to extracorporeal membrane oxygenation (ECMO) in neonates and infants.

Methods:

The aim of the study was to evaluate the individual pharmacokinetics (PK) of phenobarbital and the effect of PK covariates in neonates and infants undergoing ECMO. Sixteen patients (7 neonates, 9 infants) treated with phenobarbital during ECMO (centrifugal-flow pump circuits) were enrolled in the PK study. Phenobarbital serum concentrations were measured using a fluorescence polarization immunoassay. Individual PK parameters - volume of distribution (Vd) and clearance (CL) were calculated in a one-compartmental pharmacokinetic model.

Results:

The mean (SD) Vd and CL values in neonates were 0.46 (0.24) L/kg and 8.0 (4.5) mL/h/kg, respectively. Respective values in infants were 0.56 (0.23) L/kg and 8.5 (3.1) mL/h/kg. PK parameters in neonates and infants were not significantly different. We observed high inter-individual variability in PK parameters (coefficients of variation [CV] were 52% and 53% for CL and Vd, respectively). Doses were adjusted based on therapeutic drug monitoring (TDM) in 87.5% patients. Only 50% of the first measured phenobarbital serum concentrations in each patient were within the therapeutic range of 10-40 mg/L, in comparison with 88.6% concentration measured after TDM implementation. Linear regression models showed that both Vd and CL are significantly related with body weight (BW) and length. Median optimal phenobarbital loading dose (LD) and maintenance dose (MD), calculated from pharmacokinetic data, were 15 mg/kg and 4 mg/kg/day, respectively.

Conclusions:

Body weight was shown to be the main PK covariate of phenobarbital disposition. Subsequent dosing nomograms are provided for phenobarbital dosing during ECMO.

Keywords

ECMO infants pharmacokinetics pharmacotherapy phenobarbital

Get full access to this article

View all access options for this article.

References

Wildschut

Ahsman

Allegaert

et al . Determinants of drug absorption in different ECMO circuits. Intensive Care Med 2010; 36: 2109–2116.

Gill

Thoresen

Smit

et al . Sedation management during therapeutic hypothermia for neonatal encephalopathy: atropine premedication for endotracheal intubation causes a prolonged increase in heart rate. Resuscitation 2014; 85: 1394–1398.

Wildschut

van Saet

Pokorna

et al . The impact of extracorporeal life support and hypothermia on drug disposition in critically ill infants and children. Pediatr Clin North Am 2012; 59: 1183–1204.

Wildschut

de Wildt

Mathot

et al . Effect of hypothermia and extracorporeal life support on drug disposition in neonates. Semin Fetal Neonatal Med 2013; 18: 23–27.

Shekar

Roberts

McDonald

et al . Sequestration of drugs in the circuit may lead to therapeutic failure during extracorporeal membrane oxygenation. Crit Care 2012; 16: R194.

Kleiber

Mathot

RAA

Ahsman

et al . Population pharmacokinetics of intravenous clonidine for sedation during paediatric extracorporeal membrane oxygenation and continuous venovenous hemofiltration. Br J Clin Pharmacol 2017; 83: 1227–1239.

Shekar

Roberts

McDonald

et al . Protein-bound drugs are prone to sequestration in the extracorporeal membrane oxygenation circuit: results from an ex vivo study. Crit care 2015; 19: 164.

Raffaeli

Allegaert

Koch

et al . In vitro adsorption of analgosedative drugs in new extracorporeal membrane oxygenation circuits. Pediatr Crit Care Med 2018; doi: 10.1097/PCC.0000000000001484.

Schloss

Hayes

Jr. Tobias

JD.

Phenobarbital use in an infant requiring extracorporeal membrane life support. J Anaesthesiol Clin Pharmacol 2013; 29: 92–94.

10.

Hudak

Tan

, Committee on Drugs, Committee on Fetus and Newborn, and American Academy of Pediatrics. Neonatal drug withdrawal. Pediatrics 2012; 129: e540–560.

11.

Dillman

Messinger

Dinh

et al . Evaluation of the effects of extracorporeal membrane oxygenation on antiepileptic drug serum concentrations in pediatric patients. J Pediatr Pharmacol Ther 2017; 22: 352–357.

12.

Elliott

Buck

ML.

Phenobarbital dosing and pharmacokinetics in a neonate receiving extracorporeal membrane oxygenation. Ann Pharmacother 1999; 33: 419–422.

13.

Voller

Flint

Stolk

et al . Model-based clinical dose optimization for phenobarbital in neonates: an illustration of the importance of data sharing and external validation. Eur J Pharm Sci 2017; 109S: S90-S97.

14.

Yukawa

Suematsu

et al . Population pharmacokinetics of phenobarbital by mixed effect modelling using routine clinical pharmacokinetic data in Japanese neonates and infants: an update. J Clin Pharm Ther 2011; 36: 704–710.

15.

Gal

Boer

Toback

Erkan

NV.

Phenobarbital dosing in neonates and asphyxia. Neurology. 1982; 32: 788–789.

16.

Gal

Toback

Boer

Erkan

Wells

TJ.

Efficacy of phenobarbital monotherapy in treatment of neonatal seizures – relationship to blood levels. Neurology 1982; 32: 1401–1404.

17.

Hall

Daily

DK.

High-dose phenobarbital therapy in term newborn infants with severe perinatal asphyxia: a randomized, prospective study with three-year follow-up. J Pediatr 1998; 132: 345–348.

18.

van den Broek

Groenendaal

Toet

et al . Pharmacokinetics and clinical efficacy of phenobarbital in asphyxiated newborns treated with hypothermia: a thermopharmacological approach. Clin Pharmacokinet 2012; 51: 671–679.

19.

Fischer

Lockman

Zaske

Kriel

Phenobarbital maintenance dose requirements in treating neonatal seizures. Neurology 1981; 31: 1042–1044.

20.

Harris

Ramelet

van Dijk

et al . Clinical recommendations for pain, sedation, withdrawal and delirium assessment in critically ill infants and children: an ESPNIC position statement for healthcare professionals. Intensive Care Med 2016; 42: 972–986.

21.

Finnegan

Connaughton

Jr. Kron

Emich

JP.

Neonatal abstinence syndrome: assessment and management. Addict Dis 1975; 2: 141–158.

22.

Bonett

Price

RM.

Statistical inference for a linear function of medians: confidence intervals, hypothesis testing, and sample size requirements. Psychol Methods 2002; 7: 370–383.

23.

Pippenger

Rosen

TS.

Phenobarbital plasma levels in neonates. Clin Perinatol 1975; 2: 111–115.

24.

Mousavi

Levcovich

Mojtahedzadeh

A systematic review on pharmacokinetic changes in critically ill patients: role of extracorporeal membrane oxygenation. Daru 2011; 19: 312–321.

25.

Dagan

Klein

Gruenwald

et al . Preliminary studies of the effects of extracorporeal membrane oxygenator on the disposition of common pediatric drugs. Ther Drug Monit 1993; 15: 263–266.

26.

Sima

Pokorna

Hartinger

Slanar

Estimation of initial phenobarbital dosing in term neonates with moderate-to-severe hypoxic ischaemic encephalopathy following perinatal asphyxia. J Clin Pharm Ther 2018; 43: 196–201.